ChemPartner PharmaTechLtd Management

Management criteria checks 0/4

ChemPartner PharmaTechLtd's CEO is Swee Lian Woo, appointed in Jan 2024, has a tenure of less than a year. directly owns 4.56% of the company’s shares, worth CN¥153.07M. The average tenure of the management team and the board of directors is 1.6 years and 2.5 years respectively.

Key information

Swee Lian Woo

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	4.6%
Management average tenure	1.6yrs
Board average tenure	2.5yrs

Recent management updates

Recent updates

CEO

Swee Lian Woo (63 yo)

less than a year

Tenure

Mr. Swee Lian Woo is President of Perfect (China) Co., Ltd. He is Director of RRTC, Inc. He serves as General Manager and Chairman of Chempartner Pharmatech Co., Ltd. since January 10, 2024.He was Chairma...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jian Xu	Board Secretary	3yrs	CN¥1.44m	no data
Zhenjia Chen	Vice President	1.6yrs	CN¥1.78m	no data
Swee Lian Woo	GM & Chairman	less than a year	no data	4.56% CN¥ 153.1m

1.6yrs

Average Tenure

63yo

Average Age

Experienced Management: 300149's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Swee Lian Woo	GM & Chairman	less than a year	no data	4.56% CN¥ 153.1m
Xin Hui	Director	6.3yrs	CN¥360.00k	no data
Xuemei Zhang	Independent Director	no data	no data	no data
Rong Yu	Director	less than a year	no data	no data
Dachao Zhang	Chairman of the Supervisory Board	3.3yrs	no data	no data
Zhicheng Guo	Independent Director	4.2yrs	CN¥80.00k	no data
Shi Xin Fan	Director	3yrs	CN¥1.03m	no data
Xianzhong Wang	Independent Director	3.3yrs	CN¥80.00k	0.00030% CN¥ 10.1k
Jiahui Qi	Supervisor	6.3yrs	no data	0.0084% CN¥ 282.9k
Ling Yang	Independent Director	1.9yrs	CN¥80.00k	no data
Man Ngar Wong	Employee Supervisor	1.7yrs	no data	no data
Wanglong Chen	Non-Independent Director	no data	no data	no data

2.5yrs

Average Tenure

53.5yo

Average Age

Experienced Board: 300149's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

ChemPartner PharmaTechLtd Management

Management criteria checks 0/4

Key information

Recent management updates

ChemPartner PharmaTech Co.,Ltd. Approves the Election of Directors

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

Less than half of directors are independent

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

Less than half of directors are independent

Recent updates

ChemPartner PharmaTech Co.,Ltd. Approves the Election of Directors

ChemPartner PharmaTech Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: CN¥0.076 loss per share (vs CN¥0.011 profit in 2Q 2023)

ChemPartner PharmaTech Co.,Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 31, 2024

First quarter 2024 earnings released: CN¥0.051 loss per share (vs CN¥0.057 loss in 1Q 2023)

New minor risk - Share price stability

Chempartner Pharmatech Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024

Third quarter 2023 earnings released: CN¥0.048 loss per share (vs CN¥0.13 profit in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥1.90 in 2Q 2022)

Investor sentiment deteriorates as stock falls 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 19%

First quarter 2023 earnings released: CN¥0.057 loss per share (vs CN¥0.019 profit in 1Q 2022)

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.021 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.90 (vs CN¥0.007 in 2Q 2021)

Tate & Lyle Investments Limited completed the acquisition of Quantum Hi-Tech (Guangdong) Biological Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Tate & Lyle plc (LSE:TATE) completed the acquisition of Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149).

Chempartner Pharmatech Co., Ltd. announced that it expects to receive CNY 300 million in funding

Chempartner Pharmatech Co., Ltd., Annual General Meeting, May 23, 2022

First quarter 2022 earnings released: EPS: CN¥0.019 (vs CN¥0.003 in 1Q 2021)

Chempartner Pharmatech Co., Ltd. to Report Fiscal Year 2021 Results on Apr 30, 2022

Less than half of directors are independent

Tate & Lyle plc (LSE:TATE) signed an agreement to acquire Guangdong Quantum Hi-Tech Microecology Medical Co., Ltd. from Chempartner Pharmatech Co., Ltd. (SZSE:300149) for $237 million.

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS CN¥0.007 (vs CN¥0.11 in 2Q 2020)

Chempartner Pharmatech Co., Ltd. Announces Final Cash Dividend for 2020, Payable on 1 June 2021

Chempartner Pharmatech Co., Ltd. Approves Cash Dividend for the Year 2020

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.003 (vs CN¥0.028 loss in 1Q 2020)

Chempartner Pharmatech Co., Ltd. Announces the Profit Distribution Proposal for 2020

New 90-day low: CN¥12.64

New 90-day low: CN¥12.66

Investor sentiment deteriorated over the past week

New 90-day low: CN¥14.46

New 90-day low: CN¥18.29

Third quarter earnings released

New 90-day high - CN¥23.98

First half earnings released

Quantum Hi-Tech (China) Biological Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

New 90-day high - CN¥22.71

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age